Israel Health News API

{
    "totalArticles": 17078,
    "articles": [
        {
            "id": "337a1f3b2c1e9a05e8617cf17dc741ef",
            "title": "Dr. Stein Discusses ASH 2025 Data on Ivosidenib Plus Chemotherapy for Patients with IDH1-Mutated AML",
            "description": "Hopefully, we’ll be able to lower the rate of patients who need to go to transplant and can cure them with chemotherapy and targeted therapy alone.",
            "content": "Eytan Stein, MD, of Memorial Sloan Kettering Cancer Center, joined Cancer Nursing Today for a Q&A about his phase 1 research of ivosidenib plus intensive chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and isocitrate dehyd... [8017 chars]",
            "url": "https://www.cancernursingtoday.com/post/toxicity-trends-and-transplant-strategies-dr-stein-discusses-ash-2025-data-on-ivosidenib-plus-chemotherapy-for-patients-with-idh1-mutated-aml",
            "image": "https://mumcdnstorage.blob.core.windows.net/cnt/2026/05/DrStein_Headshot.jpeg",
            "publishedAt": "2026-05-05T22:07:45Z",
            "lang": "en",
            "source": {
                "id": "49bced55f3c95ea6592557b2620b2f72",
                "name": "Cancer Nursing Today",
                "url": "https://www.cancernursingtoday.com"
            }
        },
        {
            "id": "4c17121a92af59beef5981ab8d86801b",
            "title": "Having second autoimmune disease doesn't speed MS progression",
            "description": "Having a second autoimmune disease alongside multiple sclerosis (MS) does not accelerate disability progression, according to a study.",
            "content": "Having a second autoimmune disease does not accelerate disability progression in people with multiple sclerosis (MS), according to a large single-center study.\nAmong 1,230 MS patients followed over time, those living with an additional autoimmune con... [4084 chars]",
            "url": "https://multiplesclerosisnewstoday.com/news-posts/2026/05/05/having-second-autoimmune-disease-doesnt-speed-ms-progression/",
            "image": "https://multiplesclerosisnewstoday.com/wp-content/uploads/2026/03/iStock-1449402295-1200x630-cropped-center-top.jpg",
            "publishedAt": "2026-05-05T20:05:32Z",
            "lang": "en",
            "source": {
                "id": "a1b6d9ac23688889ceab2005a24d157c",
                "name": "Multiple Sclerosis News Today",
                "url": "https://multiplesclerosisnewstoday.com"
            }
        },
        {
            "id": "aa80a6807044198deff47fde1a3f022b",
            "title": "Breakthrough biomaterial heals tissue from the inside out",
            "description": "Scientists have developed a breakthrough injectable biomaterial that travels through the bloodstream to repair damaged tissue from within, reducing inflammation and jumpstarting healing. In animal studies, it successfully treated heart attack damage and even showed promise for conditions like traumatic brain injury and pulmonary hypertension. Unlike earlier approaches that required direct injection into the heart, this new therapy can be delivered intravenously, allowing it to spread evenly and act quickly.",
            "content": "\"This biomaterial allows for treating damaged tissue from the inside out,\" said Karen Christman, a professor of bioengineering at the University of California San Diego, and the lead researcher on the team that developed the material. \"It's a new app... [8574 chars]",
            "url": "http://www.sciencedaily.com/releases/2026/05/260504211842.htm",
            "image": "https://www.sciencedaily.com/images/1920/biomaterial-manufacturing.webp",
            "publishedAt": "2026-05-05T18:22:21Z",
            "lang": "en",
            "source": {
                "id": "8400452cd3ae520c3deec87e0653d197",
                "name": "ScienceDaily",
                "url": "http://www.sciencedaily.com"
            }
        }
    ]
}